The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Retreatment after initial treatment fail-ure for Helicobacter pylori is very challenging. The purpose of this study was to evaluate the efficacies of moxifloxacin-containing triple and bismuth-containing quadruple therapy. Methods: A total of 151 patients, who failed initial H. pylori treatment, were included in this retrospective cohort study. The initial regimens were standard triple, sequential, or concomitant therapy, and the efficacies of the two following second-line treatments were evaluated: 7-day moxifloxacin-containing triple therapy (rabeprazole 20 mg twice a day, amoxicillin 1,000 mg twice a day, and moxifloxacin 400 mg once daily) and 7-day bismuth-containing quadruple therapy (rabeprazole 20 mg twice a day, tetracycline 500 mg 4 times a day, metronidazole 500 mg 3 times a day, and tripotas-sium dicitrate bismuthate 300 mg 4 times a day). Results: The overall eradication rates after moxifloxacin-containing tri-ple therapy and bismuth-containing quadruple therapy were 69/110 (62.7%) and 32/41 (78%), respectively. Comparison of the two regimens was performed in the patients who failed standard triple therapy, and the results revealed eradi-cation rates of 14/28 (50%) and 32/41 (78%), respectively (p=0.015). The frequency of noncompliance was not differ-ent between the two groups, and there were fewer adverse effects in the moxifloxacin-containing triple therapy group (2.8% vs 7.3%, p=0.204 and 25.7% vs 43.9%, p=0.031, respectively). Conclusions: Moxifloxacin-containing triple therapy, a recommended second-line treatment for initial concomitant or sequential therapy failure, had insufficient efficacy
Abstract
Background/Aims: Retreatment after initial treatment fail-ure for Helicobacter pylori is very challenging. The purpose of this study was to evaluate the efficacies of moxifloxacin-containing triple and bismuth-containing quadruple therapy. Methods: A total of 151 patients, who failed initial H. pylori treatment, were included in this retrospective cohort study. The initial regimens were standard triple, sequential, or concomitant therapy, and the efficacies of the two following second-line treatments were evaluated: 7-day moxifloxacin-containing triple therapy (rabeprazole 20 mg twice a day, amoxicillin 1,000 mg twice a day, and moxifloxacin 400 mg once daily) and 7-day bismuth-containing quadruple therapy (rabeprazole 20 mg twice a day, tetracycline 500 mg 4 times a day, metronidazole 500 mg 3 times a day, and tripotas-sium dicitrate bismuthate 300 mg 4 times a day). Results: The overall eradication rates after moxifloxacin-containing tri-ple therapy and bismuth-containing quadruple therapy were 69/110 (62.7%) and 32/41 (78%), respectively. Comparison of the two regimens was performed in the patients who failed standard triple therapy, and the results revealed eradi-cation rates of 14/28 (50%) and 32/41 (78%), respectively (p=0.015). The frequency of noncompliance was not differ-ent between the two groups, and there were fewer adverse effects in the moxifloxacin-containing triple therapy group (2.8% vs 7.3%, p=0.204 and 25.7% vs 43.9%, p=0.031, respectively). Conclusions: Moxifloxacin-containing triple therapy, a recommended second-line treatment for initial concomitant or sequential therapy failure, had insufficient efficacy
참고문헌 (30)
- Everhart JE, "Recent developments in the epidemiology of Helicobacter pylori", Gastroenterol Clin North Am, 29, pp.559~578 (2000)
- Goh KL, "Epidemiology of Helicobacter pylori infection and public health implications", Helicobacter, 16(Suppl 1), pp.1~9 (2011)
- Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
- Essa AS, "Meta-analysis: fourdrug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication", Helicobacter, 14, pp.109~118 (2009)
- De Francesco V, "Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure", Aliment Pharmacol Ther, 19, pp.407~414 (2004)
- Oh HS, "Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study", J Gastroenterol Hepatol, 27, pp.504~509 (2012)
- Tsay FW, "Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan", J Gastroenterol Hepatol, 27, pp.498~503 (2012)
- Chan FK, "Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies", Aliment Pharmacol Ther, 14, pp.91~95 (2000)
- Hojo M, "Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection", Scand J Gastroenterol, 36, pp.690~700 (2001)
- Gisbert JP, "Review article: Helicobacter pylori “rescue”regimen when proton pump inhibitor-based triple therapies fail", Aliment Pharmacol Ther, 16, pp.1047~1057 (2002)
- Gisbert JP, "Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure", Aliment Pharmacol Ther, 23, pp.35~44 (2006)
- Saad RJ, "Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis", Am J Gastroenterol, 101, pp.488~496 (2006)
- Keating GM, "Moxifloxacin: a review of its use in the management of bacterial infections", Drugs, 64, pp.2347~2377 (2004)
- Kang JM, "Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy", Helicobacter, 12, pp.623~628 (2007)
- Cheon JH, "Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection", Helicobacter, 11, pp.46~51 (2006)
- Bago J, "Secondline treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial", Wien Klin Wochenschr, 121, pp.47~52 (2009)
- Wu C, "Moxifloxacincontaining triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection:a meta-analysis", Helicobacter, 16, pp.131~138 (2011)
- Fareed R, "Effect of Helicobacter pylori density on inflammatory activity in stomach", J Pak Med Assoc, 50, pp.148~151 (2000)
- 천재희, "Helicobacter pylori 일ㆍ이차 제균요법 실패 후Moxifloxacin 포함 삼제병합요법 시도", 대한소화기학회지, 45(2), pp.111~117 (2005), 대한소화기학회
- Nista EC, "Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection", Aliment Pharmacol Ther, 21, pp.1241~1247 (2005)
- Bago P, "High eradication rate of H. pylori with moxifloxacin-based treatment:a randomized controlled trial", Wien Klin Wochenschr, 119, pp.372~378 (2007)
- Sezgin O, "Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population", Helicobacter, 12, pp.518~522 (2007)
- Kilic ZM, "Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection", Dig Dis Sci, 53, pp.3133~3137 (2008)
- Yoon H, "Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection:effect of treatment duration and antibiotic resistance on the eradication rate", Helicobacter, 14, pp.77~85 (2009)
- Bago J, "Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial", Ann Clin Microbiol Antimicrob, 9, pp.13~ (2010)
- 김재연, "한국인의 위·십이지장 질환에 따른 Helicobacter pylori 균주의 일차 항생제 내성과 H. pylori 제균율", 대한소화기학회지, 58(2), pp.74~81 (2011), 대한소화기학회
- Lee JW, "Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea", Helicobacter, 16, pp.301~310 (2011)
- Liu G, "Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children", Helicobacter, 16, pp.356~362 (2011)
- Li Y, "Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis", Wien Klin Wochenschr, 122, pp.413~422 (2010)
- Malfertheiner P, "Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG)", Eur J Gastroenterol Hepatol, 9, pp.1~2 (1997)